Imino-tetrahydro-benzothiazole derivatives as p53 inhibitors: Discovery of a highly potent in vivo inhibitor and its action mechanism

Journal of Medicinal Chemistry

Volumn 49, Issue 12, 2006, Pages 3645-3652

  Pietrancosta, Nicolas ^a,b   Moumen, Anice ^a   Dono, Rosanna ^a   Lingor, Paul ^c   Planchamp, Veronique ^c   Lamballe, Fabienne ^a   Bähr, Mathias ^c   Kraus, Jean Louis ^a,b   Maina, Flavio ^a  

^a AIX MARSEILLE UNIVERSITÉ   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

^c UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1 (4 NITROPHENYL) 2 (4,5,6,7 TETRAHYDRO 2 IMINO 3(2H) BENZOTHIAZOLYL)ETHANONE; 2 (4 NITROPHENYL)IMIDAZO[2,1 B] 5,6,7,8 TETRAHYDROBENZOTHIAZOLE; ANTINEOPLASTIC AGENT; BENZOTHIAZOLE DERIVATIVE; CAMPTOTHECIN; ETOPOSIDE; IMINOTETRAHYDROBENZOTHIAZOLE DERIVATIVE; PIFITHRIN ALPHA; PRODRUG; PROTEIN INHIBITOR; PROTEIN P53; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DESIGN; DRUG MECHANISM; DRUG POTENCY; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NERVE CELL NECROSIS; NEUROLOGIC DISEASE; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; RAT;

ADMINISTRATION, TOPICAL; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; AXOTOMY; BENZOTHIAZOLES; CELLS, CULTURED; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DRUG DESIGN; DRUG STABILITY; ETOPOSIDE; IMINES; MALE; MICE; NEOCORTEX; NEUROPROTECTIVE AGENTS; OPTIC NERVE; PHOSPHORYLATION; PRODRUGS; RATS; RATS, WISTAR; RETINAL GANGLION CELLS; THIAZOLES; TOLUENE; TUMOR SUPPRESSOR PROTEIN P53; VITREOUS BODY;

EID: 33745142870     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm060318n     Document Type: Article

References (32)

1. Jenner, P.; Olanow, C. W. Understanding cell death in Parkinson's disease. Ann. Neural. 1998, 44, S72-84.
2. Dirnagl, U.; Iadecola, C.; Moskowitz, M. A. Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci. 1999, 22, 391-397.
3. Mattson, M. P. Apoptosis in neurodegenerative disorders. Nat. Rev. Mol. Cell. Biol. 2000, 1, 120-129.
4. Green, V. J.; Kokkotou, E.; Ladias, J. A. Critical structural elements and multitarget protein interactions of the transcriptional activator AF-1 of hepatocyte nuclear factor 4. J. Biol. Chem. 1998, 273. 29950-29957.
5. Blum, D.; Wu, Y.; Nissou, M. F.; Arnaud, S.; Alim Louis, B.; Verna, J. M. p53 and Bax activation in 6-hydroxydopamine-induced apoptosis in PC12 cells. Brain Res. 1997, 751, 139-142.
6. Sakhi, S.; Bruce, A.; Sun, N.; Tocco, G.; Baudry, M.; Schreiber, S. S. Induction of tumor suppressor p53 and DNA fragmentation in organotypic hippocampal cultures following excitotoxin treatment. Exp. Neurol. 1997, 145, 81-88.
7. Xiang, H.; Kinoshita, Y.; Knudson, C. M.; Korsmeyer, S. J.; Schwartzkroin, P. A.; Morrison, R. S. Bax involvement in p53-mediated neuronal cell death. J. Neurosci. 1998, 18, 1363-1373.
8. Cregan, S. P.; MacLaurin, J. G.; Craig, C. G.; Robertson, G. S.; Nicholson, D. W.; Park, D. S.; Slack, R. S. Bax-dependent caspase-3 activation is a key determinant in p53-induced apoptosis in neurons. J. Neumsci. 1999, 19, 7860-7869.
9. Uberti, D.; Belloni, M.; Grilli, M.; Spano, P.; Memo, M. Induction of tumour-suppressor phosphoprotein p53 in the apoptosis of cultured rat cerebellar neurones triggered by excitatory amino acids. Eur. J. Neurosci 1998, 10, 246-254.
10. Crumrine, R. C.; Thomas, A. L.; Morgan, P. F. Attenuation of p53 expression protects against focal ischemic damage in transgenic mice. J. Cereb. Blood Flow Metab. 1994, 14, 887-891.
11. Li, R.; Waga, S.; Hannon, G. J.; Beach, D.; Stillman, B. Differential effects by the p21 CDK inhibitor on PCNA-dependent DNA replication and repair. Nature 1994, 371, 534-537.
12. Napieralski, J. A.; Raghupathi, R.; McIntosh, T. K. The tumor-suppressor gene, p53, is induced in injured brain regions following experimental traumatic brain injury. Brain Res. Mol. Brain Res. 1999, 71, 78-86.
13. de la Monte, S. M.; Sohn, Y. K.; Wands, J. R. Correlates of p53-and Fas (CD95)-mediated apoptosis in Alzheimer's disease. J. Neurol. Sci. 1997, 152, 73-83.
14. Jeffers, J. R.; Parganas, E.; Lee, Y.; Yang, C.; Wang, J.; Brennan, J.; MacLean, K. H.; Han, J.; Chittenden, T.; Ihle, J. N.; McKinnon, P. J.; Cleveland, J. L.; Zambetti, G. P. Puma is an essential mediator of p53-dependent and -independent apoptotic pathways. Cancer Cell 2003, 4, 321-328.
15. Moll, U. M.; Wolff, S.; Speidel, D.; Deppert, W. Transcription- independent pro-apoptotic functions of p53. Curr. Opin. Cell Biol. 2005, 17, 631-636.
16. Komarov, P. G.; Komarova, E. A.; Kondratov, R. V.; Christov-Tselkov, K.; Coon, J. S.; Chernov, M. V.; Gudkov, A. V. A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science 1999, 285, 1733-1737.
17. Culmsee, C.; Zhu, X.; Yu, Q. S.; Chan, S. L.; Camandola, S.; Guo, Z.; Greig, N. H.; Mattson, M. P. A synthetic inhibitor of p53 protects neurons against death induced by ischemic and excitotoxic insults, and amyloid beta-peptide. J. Neurochem. 2001, 77, 220-228.
18. Zhu, X.; Yu, Q. S.; Cutler, R. G.; Culmsee, C. W.; Holloway, H. W.; Lahiri, D. K.; Mattson, M. P.; Greig, N. H. Novel p53 inactivators with neuroprotective action: syntheses and pharmacological evaluation of 2-imino-2,3,4,5,6,7-hexahydroben7,othiazole and 2-imino-2,3,4,5,6,7- hexahydrobenzoxazole derivatives. J. Med. Chem. 2002, 45, 5090-5097.
19. Duan, W.; Zhu, X.; Ladenheim, B.; Yu, Q. S.; Guo, Z.; Oyler, J.; Cutler, R. G.; Cadet, J. L.; Greig, N. H.; Mattson, M. P. p53 inhibitors preserve dopamine neurons and motor function in experimental parkinsonism. Ann. Neurol. 2002, 52, 597-606.
20. Pietrancosta, N.; Maina, F.; Dono, R.; Moumen, A.; Garino, C.; Laras, Y.; Burlet, S.; Quelever, G.; Kraus, J. L. Novel cyclized Pifithrinalpha p53 inactivators: synthesis and biological studies. Bioorg. Med. Chem. Lett. 2005, 15, 1561-1564.
21. Barchechath, S. D.; Tawatao, R. I.; Corr, M.; Carson, D. A.; Cottam. H. B. Inhibitors of apoptosis in lymphocytes: Synthesis and biological evaluation of compounds related to pifithrin-alpha. J. Med. Chem. 2005, 48, 6409-6422.
22. Johnson, M.; Lajiness, M.; Maggiora, G. Molecular similarity: a basis for designing drug screening programs. Prog. Clin. Biol. Res. 1989, 291, 167-171.
23. Evans, B. E.; Rittle, K. E.; Bock, M. G.; DiPardo, R. M.; Freidinger, R. M.; Whitter, W. L.; Lundell, G. F.; Veber, D. F.; Anderson, P. S.; Chang, R. S.; et al. Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists. J. Med. Chem. 1988, 31, 2235-2246.
24. King, L. C.; Hlavacek, R. The reaction of ketones with iodine and thiourea. J. Am. Chem. Sac. 1950, 72, 3722-3725.
25. Tulasne, D.; Deheuninck, J.; Lourenco, F. C.; Lamballe, F.; Ji, Z.; Leroy, C.; Puchois, E.; Moumen, A.; Maina, F.; Mehlen, P.; Fafeur. V. Proapoptotic function of the MET tyrosine kinase receptor through caspase cleavage. Mol. Cell. Biol. 2004, 24, 10328-10339.
26. Thompson, T.; Tovar, C.; Yang, H.; Carvajal, D.; Vu, B. T.; Xu, Q.; Wahl, G. M.; Heimbrook, D. C.; Vassilev, L. T. Phosphorylation of p53 on key serines is dispensable for transcriptional activation and apoptosis. J. Biol. Chem. 2004, 279, 53015-53022.
27. Arriola, E. L.; Lopez, A. R.; Chresta, C. M. Differential regulation of p21waf-l/cip-1 and Mdm2 by etoposide: etoposide inhibits the p53-Mdm2 autoregulatory feedback loop. Oncogene 1999, 18, 1081-1091.
28. Bae, B. I.; Xu, H.; lgarashi, S.; Fujimuro, M.; Agrawal, N.; Taya, Y.; Hayward, S. D.; Moran, T. H.; Montell, C.; Ross, C. A.; Snyder, S. H.; Sawa, A. p53 mediates cellular dysfunction and behavioral abnormalities in Huntington's disease. Neuron 2005, 47, 29-41.
29. Greene, W.; Wunts, P. G. Protective Groups in Organic Synthesis. 3rd ed.; John Wiley and Sons: New York, 1999; Vol. 1.
30. Gary, R. K.; Jensen, D. A. The p53 inhibitor pifithrin-alpha forms a sparingly soluble derivative via intramolecular cyclization under physiological conditions. Mol. Pharm. 2005, 2, 462-474.
31. Maina, F.; Pante, G.; Helmbacher, F.; Andres, R.; Porthin, A.; Davies, A. M.; Ponzetto, C.; Klein, R. Coupling Met to specific pathways results in distinct developmental outcomes. Mol. Cell 2001, 7, 1293-1306.
32. Kermer, P.; Klocker, N.; Weishaupt, J. H.; Bahr, M. Transection of the optic nerve in rats: studying neuronal death and survival in vivo. Brain Res. Brain Res. Protoc. 2001, 7, 255-260.